Beta-lactamase and antibiotic resistance: three ways bacteria win
Bacteria resist beta-lactams by destroying the drug, changing its target or keeping it out. Only the first can be beaten by a beta-lactamase inhibitor such as clavulanate.
Explain beta-lactamase, altered PBP and porin mechanisms of resistance and how beta-lactamase inhibitors restore activity.
The short version
- Beta-lactams block cell wall building by binding the penicillin-binding proteins (PBPs); bacteria resist by destroying the drug, changing the target or keeping the drug out.
- Beta-lactamases hydrolyse the beta-lactam ring and are the most common beta-lactam resistance mechanism, especially in gram-negatives.
- Clavulanate, sulbactam and tazobactam disable the enzyme and protect the partner antibiotic; they are used for that protection, not for their own killing, and do not touch zinc-dependent metallo-beta-lactamases.
- MRSA makes PBP2a through the mecA gene; it keeps building the wall, resists nearly every beta-lactam and is not rescued by an inhibitor.
- Porins and efflux pumps keep drug out and matter in gram-negatives, which have an outer membrane; mechanisms often combine.
Beta-lactamase and antibiotic resistance: the inhibitor puzzle
A little girl's ear infection will not settle on amoxicillin. Her doctor switches to amoxicillin plus a second drug that barely kills bacteria on its own, and now it works.
How can a drug with almost no antibacterial power rescue another? The answer lies in the three ways bacteria resist beta-lactams, and in which of them an inhibitor can beat. This page covers beta-lactamase and antibiotic resistance in that order.
The beta-lactam ring and the penicillin-binding proteins
Beta-lactams, the penicillins and cephalosporins among them, share a four-membered beta-lactam ring.[1][8]
They bind the penicillin-binding proteins (PBPs), which cross-link the cell wall, and that blocks the wall being built.[2][8]
Every resistance mechanism in this lesson is a way of undoing one of these two facts: the drug carries a ring that can be broken, and it must reach and bind a PBP to work. Break the ring, change the PBP, or stop the drug arriving, and the wall keeps being built.
Three ways bacteria resist beta-lactams
A bacterium has three ways to survive a beta-lactam.[1][2]
- Destroy the drug: beta-lactamases hydrolyse the ring.
- Change the target: an altered PBP binds the drug poorly.
- Keep the drug out: fewer or altered porins, plus efflux pumps.
Each one is taught below, together with whether a beta-lactamase inhibitor can help. Keep that second question in mind, because it is what separates the three mechanisms on an exam.
Efflux pumps sit in the third group because the drug may enter and then be pushed straight back out.[1][2]
Mechanism one: beta-lactamases destroy the drug, and inhibitors block them
Beta-lactamases hydrolyse the beta-lactam ring, and the drug loses its activity. This is the most common beta-lactam resistance mechanism, especially in gram-negatives.[1][2]
The genes often sit on plasmids that spread between bacteria.[1][4]
| Enzyme | What it breaks |
|---|---|
| Penicillinase | Penicillins |
| Extended-spectrum beta-lactamase | Penicillins and cephalosporins, but not carbapenems |
| Carbapenemase | Penicillins, cephalosporins and carbapenems |
| Metallo-beta-lactamase | Penicillins, cephalosporins and carbapenems; zinc-dependent, so the classic inhibitors do not touch it |
Reading the first three rows from top to bottom, each enzyme breaks everything the one above it breaks, plus more.[1][2]
Metallo-beta-lactamases are set apart by their zinc dependence: the classic inhibitors do not touch them.[3]
An inhibitor carries a beta-lactam ring of its own. It binds the enzyme's active site and disables it, which protects the partner antibiotic.[1][3]
Clavulanate on its own does almost nothing. That answers the opening puzzle: amoxicillin kills, and clavulanate guards it.[1]
So the combination divides the labour. The partner beta-lactam does the killing; the inhibitor stops the enzyme from destroying it.
Mechanism two: altered PBPs and MRSA
MRSA carries the mecA gene, which makes PBP2a, a penicillin-binding protein with low affinity for beta-lactams.[2][7]
The wall is still built, so the bacterium survives nearly every beta-lactam; the fifth-generation cephalosporins such as ceftaroline were designed as the exception.[1][8]
An inhibitor cannot help, because no enzyme is destroying the drug.
Pneumococci reach resistance a similar way, by altering their own PBPs.[1][6]
Mechanism three: porins and efflux keep the drug out
A gram-negative outer membrane lets beta-lactams in through porin channels. Fewer or altered porins mean less drug enters.[2][4]
Pseudomonas lowers its OprD porin to resist carbapenems.[1][2]
Efflux pumps that push drug out add to this in many species.[1][2]
The mechanisms combine. A gram-negative rod with fewer porins lets in less drug, and its beta-lactamase destroys the little that arrives.[4]
Telling the mechanisms apart
| Clue | Think |
|---|---|
| An inhibitor restores susceptibility | Beta-lactamase |
| A gram-positive coccus resists nearly every beta-lactam, inhibitor combinations included | Altered PBP |
| The organism is gram-negative (has an outer membrane) | Porins can also matter |
- Does an inhibitor restore susceptibility?If so, think beta-lactamase.
- Is it a gram-positive coccus resisting nearly every beta-lactam, inhibitor combinations included?Think altered PBP.
- Is it a gram-negative?Porins can matter too, because only gram-negatives have an outer membrane.
Practice question
Original · USMLE styleA 58-year-old man with diabetes mellitus has a draining wound over his heel. Bone culture grows Staphylococcus aureus. Susceptibility testing shows the isolate is resistant to oxacillin, cefazolin and amoxicillin-clavulanate and susceptible to vancomycin.
Common questions
What is a beta-lactamase?
An enzyme that hydrolyses the beta-lactam ring, so the drug loses its activity. It is the most common beta-lactam resistance mechanism, especially in gram-negatives.
How do clavulanate, sulbactam and tazobactam work?
Each carries a beta-lactam ring of its own and binds the enzyme's active site, disabling it. That protects the partner antibiotic. They are given for that protection, not for their own antibacterial activity; clavulanate on its own does almost nothing.
Why can an inhibitor not help against MRSA?
MRSA resists through PBP2a, an altered target, not through an enzyme destroying the drug. With no enzyme to block, an inhibitor has nothing to disable.
What are the three mechanisms of beta-lactam resistance?
Destroy the drug with beta-lactamases, change the target with an altered PBP, or keep the drug out with fewer porins and efflux pumps.
Which resistance mechanism needs an outer membrane?
Porin loss. Porin channels cross the outer membrane of gram-negative bacteria, so this mechanism does not apply to gram-positive organisms.
Transcript
Read the full narration, by chapter599 words
0:00The hook: amoxicillin plus a second drug
A little girl's ear infection will not settle on amoxicillin. Her doctor switches to amoxicillin plus a second drug that barely kills bacteria on its own, and now it works. How can a drug with almost no antibacterial power rescue another? Today: the three ways bacteria resist beta-lactams, and which one an inhibitor can beat.
0:22The beta-lactam ring and the penicillin-binding proteins
Beta-lactams, the penicillins and cephalosporins among them, share a four-membered beta-lactam ring. They bind the penicillin-binding proteins, the PB Ps, which cross-link the cell wall, and that blocks the wall being built. A bacterium has three ways to survive: destroy the drug, change the target, or keep the drug out.
0:45Mechanism one: destroy it (beta-lactamases)
One, destroy it. Beta-lactamases hydrolyse the beta-lactam ring, and the drug loses its activity. This is the most common beta-lactam resistance mechanism, especially in gram-negatives, and the genes often sit on plasmids that spread between bacteria. Penicillinases break penicillins. Extended-spectrum enzymes also break cephalosporins, but not carbapenems. Carbapenemases break those too. The classic inhibitors do not touch the zinc-dependent metallo-beta-lactamases.
1:20Beta-lactamase inhibitors: clavulanate, sulbactam, tazobactam
An inhibitor, clavulanate, sulbactam or tazobactam, carries a beta-lactam ring of its own. It binds the enzyme's active site and disables it, which protects the partner antibiotic. On its own it does almost nothing. That answers our hook: amoxicillin kills, clavulanate guards it.
1:42Mechanism two: change the target (MRSA and PBP2a)
Two, change the target. MRSA carries the mecA gene, which makes PBP2a, a penicillin-binding protein with low affinity for beta-lactams. The wall is still built, so the bacterium survives nearly every beta-lactam; ceftaroline was designed as the exception. An inhibitor cannot help, because no enzyme is destroying the drug. Pneumococci reach resistance a similar way, by altering their own PB Ps.
2:13Mechanism three: keep it out (porins and efflux)
Three, keep it out. A gram-negative outer membrane lets beta-lactams in through porin channels. Fewer or altered porins mean less drug enters. Pseudomonas lowers its OprD porin to resist carbapenems. Efflux pumps that push drug out add to this in many species. The mechanisms combine. A gram-negative rod with fewer porins lets in less drug, and its beta-lactamase destroys the little that arrives.
2:44Tell the mechanisms apart
To tell them apart: if an inhibitor restores susceptibility, think beta-lactamase. If a gram-positive coccus resists nearly every beta-lactam, inhibitor combinations included, think altered PBP. Porins matter only in gram-negatives, which have an outer membrane.
3:04Practice question: a draining heel wound, S. aureus
Your turn. A 58-year-old man with diabetes has a draining wound over his heel, and bone culture grows Staphylococcus aureus. The isolate is resistant to oxacillin, cefazolin and amoxicillin-clavulanate, and susceptible to vancomycin. Which of the following best explains this resistance? A, hydrolysis of the beta-lactam ring by a plasmid-encoded enzyme. B, production of a penicillin-binding protein with low affinity for beta-lactams. C, reduced numbers of outer membrane porin channels. D, alteration of the cell wall precursor so that vancomycin cannot bind. E, alteration of the ribosomal subunit that the antibiotic binds. Pause here and decide. A is out: a beta-lactamase would be blocked by the clavulanate, and oxacillin is a penicillinase-resistant penicillin, yet this isolate resists both. C is out: Staphylococcus aureus is gram-positive, so it has no outer membrane and no porins to lose. D is out: that change causes vancomycin resistance, and this isolate is susceptible to vancomycin. E is out: ribosomal changes give resistance to macrolides and other protein-synthesis inhibitors, not to beta-lactams.
4:32The answer: altered PBP
So the answer is B. MRSA makes PBP2a, which keeps building the wall while binding beta-lactams poorly.
4:43High-yield recap and next lesson
Three things to keep. One: beta-lactamases hydrolyse the ring, and clavulanate, sulbactam and tazobactam block them. Two: an altered PBP, as in MRSA, defeats nearly every beta-lactam, inhibitor or not. Three: gram-negatives also keep drug out, with fewer porins and with pumps. Next, DNA versus RNA virus replication.
Sources
Numbers in the text, e.g. [1], point here- Drug resistance (enzymatic inactivation, target modification, uptake and efflux, beta-lactamase inhibitors, MRSA, pneumococci, OprD). OpenStax Microbiology, section 14.5. openstax.org/books/microbiology/pages/14-5-drug-resistance
- Mechanisms of antimicrobial resistance in ESKAPE pathogens (beta-lactamases, PBP2a, porins, efflux). Europe PMC PMC4871955. europepmc.org/article/PMC/PMC4871955
- Structural perspectives on clinical beta-lactamase inhibitors. J Microbiol 2026. Europe PMC PMC13577047. europepmc.org/article/PMC/PMC13577047
- Antimicrobial resistance in Gram-negative bacteria. J Microbiol 2026. Europe PMC PMC13688131. europepmc.org/article/PMC/PMC13688131
- Antimicrobial resistance in major Gram-positive pathogens, 2026. Europe PMC PMC13509171. europepmc.org/article/PMC/PMC13509171
- Pneumococcal resistance and PBP alterations. Europe PMC PMC13414315 and PMC13561796. europepmc.org/article/PMC/PMC13414315 · europepmc.org/article/PMC/PMC13561796
- Oxacillin and penicillinase-resistant penicillins, mecA/PBP2a. Europe PMC PMC13706667. europepmc.org/article/PMC/PMC13706667
- Beta-lactamase; Penicillin-binding proteins; Methicillin-resistant Staphylococcus aureus. Wikipedia (background). en.wikipedia.org/wiki/Beta-lactamase · en.wikipedia.org/wiki/Penicillin-binding_proteins · en.wikipedia.org/wiki/Methicillin-resistant_Staphylococcus_aureus
The practice question is original and its patient is synthetic. Every fact is checked against the sources above in independent accuracy reviews. Always follow your local guidelines and your own laboratory’s ranges.
Image credits. Illustrations: Servier Medical Art (smart.servier.com), CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), adapted (recoloured, outlined): ear (otitis media cue), amoxicillin and inhibitor capsules, bacterium. NIAID NIH BioArt Source (bioart.niaid.nih.gov), public domain, adapted (recoloured, outlined): Staphylococcus aureus, protein pore (porin channels), gram-negative bacterium. Health Icons (healthicons.org), CC0: child icon. Original diagrams drawn in code: the beta-lactam ring, enzymes and active site, penicillin-binding proteins and the cell wall, plasmids, the enzyme-spectrum table, the susceptibility strip, the gram-negative envelope and all handwriting. No AI-generated teaching images.
Corrections. None so far. Spotted an error? Email info@medservatory.com with the lesson code MS-S1-MICRO-007.
For exam study only, not medical advice. Read the medical disclaimer.
In this series
Playlist on YouTube- EP 01Gram-positive vs gram-negative cell walls5:39
- EP 02Acid-fast stain and the mycobacterial cell wall5:01
- EP 03Endotoxin vs exotoxin: lipid A, A-B toxins and toxoids5:46
- EP 04Bacterial toxins that raise cAMP: cholera, pertussis, anthrax5:54
- EP 05Clostridial toxins compared: tetanus, botulinum, alpha, C. difficile5:22
- EP 06Staph vs strep: catalase, coagulase and haemolysis5:23
- EP 07Encapsulated organisms and the spleen: asplenia and conjugate vaccines5:08
- EP 08Bacterial genetics: how bacteria swap genes5:13
- EP 09Beta-lactamase and antibiotic resistance: three ways bacteria win5:13
- EP 10DNA vs RNA virus replication: which enzyme each genome needs5:48
- EP 11HIV life cycle and drug targets, step by step5:39
- EP 12Hepatitis B serology: reading the panel5:17
- EP 13Antifungal drugs explained: mechanisms of action5:26
- EP 14Bacterial meningitis organisms by age and risk group5:19